US EditionRoche CEO points to higher future drug prices in Switzerland after US deal
Roche CEO Thomas Schinecker warns U.S. drug price deals could increase costs for new medicines in Switzerland, which accounts for 10% of its GDP, affecting research investment.
- On Dec 20, Roche Chief Executive Thomas Schinecker warned deals between pharmaceutical companies and Washington will likely push up new drug costs in Switzerland and urged higher payments to align prices with Washington.
- The White House's pressure prompted voluntary deals after U.S. President Donald Trump sent a summer letter to 17 major companies, with Genentech among 14 firms signing on to cut U.S. drug prices.
- Most Favoured Nation pricing commits companies like Genentech to match the lowest price in wealthy countries including Switzerland, while Schinecker said existing medicines stay stable initially and future launches will follow this system.
- Negotiators in Bern face pressure as Schinecker warned resistance to raising Swiss drug prices could cause knock-on effects, while Swiss politicians voice concern despite price cuts for the U.S. Medicaid program.
- Given Swiss GDP per capita exceeds the United States, Schinecker said prices will rise gradually with each new launch over the coming years and cautioned that 'Unfortunately, this would likely lead to further delays in introducing new medicines.
19 Articles
19 Articles
The price cuts obtained last Friday by Donald Trump from the giants of pharma, including Roche and Novartis, will put pressure on the prices of medicines in Switzerland. One of Washington's objectives is to obtain more equitable financing of innovationSought by the US government in its quest to get a drop in the price of medicines in the United States, Novartis and Roche, through its subsidiary Genentech, signed on Friday an agreement with the W…
While the US administration announced on Friday an agreement with nine new laboratories to reduce drug prices, Thomas Schinecker believes that Switzerland is the country that has "the most to win and the most to lose" in the new equation.
Roche CEO points to higher future drug prices in Switzerland after US deal
Deals between pharmaceutical companies and Washington to reduce prices for medicines in the United States will likely push up the cost of new drugs in Switzerland, the CEO of Swiss pharma giant Roche was quoted as saying on Saturday.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
